September 7, 2016
Daiichi Sankyo, Inc. (Edison,NJ) announced the appointment of Marielle Cohard-Radice, M.D., as Executive Vice President, Global Head of Development.
In her new role, Dr. Cohard-Radice will have responsibility for the development strategy and portfolio planning for the Cardiovascular-Metabolism and Internal Medicine therapeutic areas.
Prior to her promotion, Marielle Cohard-Radice was Vice President of Clinical Development Operations at Daiichi Sankyo Pharma Development, a position she held since 2012.
The former Global Head of Development, Mahmoud Ghazzi, M.D., Ph.D, has decided to leave the company.
The Impact of Artificial Intelligence on the Creation of Medicines
October 24th 2024Najat Khan, chief R&D officer, chief commercial officer, Recursion, and Fred Hassan, director, Warburg Pincus, discuss how artificial intelligence can help reduce healthcare costs at the 20th Annual Young & Partners Pharmaceutical Executive Summit held at the Yale Club of New York.
Plan Ahead: Mastering Your AI Budget for 2025 Success
October 9th 2024Generative AI is just one part of the artificial intelligence and machine learning that is being used by life science organizations, emerging as a major area of interest and an area in which costs and ROI are still largely unknown.